Haematuria, a Widespread Petechial Rash, and Headaches Following the Oxford AstraZeneca ChAdOx1 NCoV-19 Vaccination
Overview
Authors
Affiliations
With increasing presentations of headaches following COVID-19 vaccination, we present one of the UK's earliest proven cases of vaccine-induced thrombotic thrombocytopaenia (VITT), with the aim of giving colleagues a case to compare other patients against. Our patient was a 48-year-old man who presented with frank haematuria, a widespread petechial rash, and headaches, 2 weeks after receiving the first dose of the Oxford AstraZeneca ChAdOx1 nCoV-19 vaccine. He had a platelet count of 14×10/L and an extensive cerebral venous sinus thrombosis (CVST) with subarachnoid haemorrhage on imaging. He developed localising neurological signs and experienced a cardiopulmonary arrest. He was successfully resuscitated and transferred to a tertiary care centre for urgent thrombectomy. This case illustrates how the diagnosis of VITT should be based on the platelet count and imaging-and how patients with VITT should be cared for in centres with urgent neurosurgical and interventional radiology services.
Bin Rubaian N, Aljalfan A, Almuhaidib S J Family Community Med. 2023; 30(3):161-170.
PMID: 37675215 PMC: 10479027. DOI: 10.4103/jfcm.jfcm_3_23.
Neurological Adverse Reactions to SARS-CoV-2 Vaccines.
Finsterer J Clin Psychopharmacol Neurosci. 2023; 21(2):222-239.
PMID: 37119215 PMC: 10157009. DOI: 10.9758/cpn.2023.21.2.222.
Endovascular Treatment of Intracranial Vein and Venous Sinus Thrombosis-A Systematic Review.
Bucke P, Hellstern V, Cimpoca A, Cohen J, Horvath T, Ganslandt O J Clin Med. 2022; 11(14).
PMID: 35887982 PMC: 9319519. DOI: 10.3390/jcm11144215.
Washrawirul C, Triwatcharikorn J, Phannajit J, Ullman M, Susantitaphong P, Rerknimitr P J Eur Acad Dermatol Venereol. 2022; 36(11):1947-1968.
PMID: 35666609 PMC: 9348179. DOI: 10.1111/jdv.18294.
Garcia-Azorin D, Lazaro E, Ezpeleta D, Lecumberri R, de la Camara R, Castellanos M Neurologia. 2022; .
PMID: 35645442 PMC: 9124923. DOI: 10.1016/j.nrl.2022.04.010.